Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 5881 - 5888 of 12029 results
Biosimilars Action Plan Update: Public Hearing Scheduled
July 24, 2018| Blog| Viewpoint
Comcast Bows Out of Fox Bidding
July 24, 2018| News
Are Third-Party Funding Costs Recoverable in Arbitration?
July 23, 2018| Blog| Viewpoint
The Four Things You Need To Know About The Future of Energy Efficiency
July 23, 2018| Blog| Viewpoint
CMS Focuses on a Modern Medicare
July 23, 2018| Blog| Viewpoint
ML Strategies Weekly Health Care Preview – July 23, 2018
July 23, 2018| Blog| Viewpoint
CMS Proposes to Reduce Payments for New Drugs under Medicare Part B
July 20, 2018| Blog| Viewpoint
Does USCIS Want to Turn Lawful Immigrants into Unlawful, Removable Immigrants? The Answer it seems, is “Yes”
July 20, 2018| Blog| Viewpoint
News & Press Releases
San Francisco Business Times featured Mintz’s new office lease in San Francisco at 525 Market St. The firm will be increasing its footprint in downtown by 50% to 29,000 square feet on a whole single floor with the new space.
Mintz advised the underwriters in connection with a $230 million public offering by Cogent Biosciences, Inc. of 25,555,556 shares of common stock, which includes 3,333,333 shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering were approximately $230 million, including proceeds from the exercise in full by the underwriters of the option to purchase additional shares, before deducting underwriting discounts and commissions and other offering expenses.
Mintz advised the underwriters in connection with a $200 million public offering by Soleno Therapeutics, Inc. of 2,352,941 shares of its common stock at a price to the public of $85.00 per share. The gross proceeds to Soleno from the offering were approximately $200 million before deducting underwriting discounts and commissions and other offering expenses. In addition, Soleno granted the underwriters a 30-day option to purchase up to an additional 352,941 shares of its common stock at the public offering price.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|